Feb 5 (Reuters) - Rani Therapeutics Holdings Inc RANI.O:
RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING SUCCESSFUL ORAL DELIVERY OF SEMAGLUTIDE VIA RANIPILL® HC
RANI THERAPEUTICS HOLDINGS INC - RT-116 WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
RANI THERAPEUTICS HOLDINGS INC - PHASE 1 STUDY FOR RT-114 EXPECTED TO INITIATE IN 2025
Source text: ID:nGNX3fYhzr
Further company coverage: RANI.O